Form 8-K

8-K — Inmune Bio, Inc.

Accession: 0001213900-26-073983

Filed: 2026-07-01

Period: 2026-06-30

CIK: 0001711754

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Entry into a Material Definitive Agreement

Item: Financial Statements and Exhibits

Documents

8-K — ea0296624-8k_inmune.htm (Primary)

EX-4.1 — FORM OF AMENDMENT TO COMMON STOCK PURCHASE WARRANT (ea029662401ex4-1.htm)

EX-10.1 — FORM OF INDUCEMENT LETTER (ea029662401ex10-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0296624-8k_inmune.htm · Sequence: 1

false

0001711754

2026-06-30

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

June 30, 2026

INMUNE BIO INC.

(Exact name of registrant as specified in charter)

Nevada

001-38793

47-5205835

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of incorporation)

Identification No.)

225 NE Mizner Blvd., Suite 640, Boca Raton,

Florida 33432

(Address of Principal Executive Offices) (Zip Code)

(561) 710-0512

(Registrant’s Telephone Number, Including

Area Code)

Not Applicable

(Former Name or Former Address, If Changed Since

Last Report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction

A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per shares

INMB

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On June 30, 2026, INmune

Bio Inc. (the Company”) entered into a warrant inducement offer letter agreement (the “Inducement Letter”) and into

an amendment to common stock purchase warrant (the “Second Amendment”) with certain holders (the “Holders”) of

common stock purchase warrants previously issued by the Company in its April 2024 offerings on April 24, 2024 and April 29, 2024, as such

warrants were amended on December 22, 2025 (the “April 2024 Warrants”).

Pursuant to the Inducement

Letter the Company offered the Holders the opportunity to exercise 50% of the April 2024 Warrants held by them for a reduced exercise

price per share equal to $1.40 (reduced from $1.95) (the “Reduced Exercise Price”) and to amend the April 2024 Warrants such

that the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were not exercised

pursuant to the Inducement Letter, shall be extended from June 30, 2026, to December 31, 2027.

Pursuant to the Inducement

Letter, Holders agreed to exercise, for cash, 647,112 April 2024 Warrants, representing 50% of the April 2024 Warrants held by such Holders,

and have agreed to purchase an aggregate of 647,112 shares of common stock at the Reduced Exercise Price in exchange for the Company’s

agreement to extend the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were

not exercised pursuant to the Inducement Letter, from June 30, 2026, to December 31, 2027. The Company expects to receive an aggregate

of $905,957 as consideration for the exercise of the said 50% of the April 2024 Warrants.

Pursuant to the Second

Amendment, the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were not exercised

pursuant to the Inducement Letter, was extended from June 30, 2026, to December 31, 2027.

The issuance, or resale,

of shares of common stock underlying the April 2024 Warrant have been registered pursuant to an effective registration statement (File

No. 333-279036). The Registration Statement is currently effective and, upon exercise of 50% the April 2024 Warrant pursuant to Inducement

Letter will be effective for the issuance or resale of the shares of common stock underlying the April 2024 Warrants, as applicable.

The foregoing summary

of the Inducement Letter and the Second Amendment does not purport to be complete and is qualified in its entirety by reference to the

form of the Inducement Letter and the Second Amendment, a copy of which is filed as Exhibits 4.1 and 10.1 hereto and incorporated herein

by reference.

Item 9.01 Financial statements and Exhibits

(d) Exhibits.

4.1

Form of Amendment to Common Stock Purchase Warrant

10.1

Form of Inducement Letter

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INMUNE BIO INC.

Date: July 1, 2026

By:

/s/ David Moss

Name:

David Moss

Title:

Chief Executive Officer

EX-4.1 — FORM OF AMENDMENT TO COMMON STOCK PURCHASE WARRANT

EX-4.1

Filename: ea029662401ex4-1.htm · Sequence: 2

Exhibit 4.1

FORM OF AMENDMENT TO WARRANT

This Second Amendment to Common Stock Purchase

Warrant (this “Amendment”) is entered into and shall become effective as of the date on which INmune Bio Inc. a Nevada corporation

(the “Company”) receives both (i) payment of the Amendment Consideration (as defined below) and (ii) a duly executed copy

of this Amendment from the undersigned holder (“Holder”) (such date, the “Effective Date”).

WHEREAS, the Holder is the holder of that certain

warrant issued by the Company to the Holder on April 24 or April 29, 2024 (the “Warrant”);

WHEREAS, the Company and the Holder desire to

amend the Warrant as more particularly set forth below in exchange for the Amendment Consideration; WHEREFORE, the parties do hereby agree

as follows:

1. The

portion of the Warrant’s first paragraph:

“and on or prior to 5:00pm (New York City

time) on June 30, 2026,”

is hereby amended and replaced with the following:

“and on or prior to 5:00pm (New York City

time) on December 31, 2027”

2. As

consideration for this Amendment, the Company has granted the Holder the option to exercise 50% of the warrant for a reduced exercise

price of $1.40 per share of Common Stock and the Holder elected to exercise 50% of the warrant for such reduced price and has paid the

Company such reduced exercised price (the “Amendment Consideration”). The effectiveness of this Amendment is expressly conditioned

upon the Company’s receipt of the full Amendment Consideration.

3. The

Holder must execute and return this Amendment to the Company, together with the Amendment Consideration, no later than June 30, 2026 (the

“Execution Deadline”). If the Holder does not execute and return this Amendment, together with the Amendment Consideration,

to the Company by the Execution Deadline, this Amendment shall be null and void and of no force or effect.

4. Except

as expressly amended herein, all terms and conditions of the Warrant shall remain in full force and effect.

5. This

Amendment shall be governed by and construed in accordance with the laws governing the Warrant.

6. This

Amendment may be executed in counterparts, each of which shall be deemed an original, and shall be binding upon all parties, their successors

and assigns, and all of which taken together shall constitute one and the same Amendment. A signature delivered by facsimile or email

shall constitute an original.

[Signature Page Follows]

INmune Bio Inc.

By:

Name:

Title:

Holder:

By:

Name:

Title:

EX-10.1 — FORM OF INDUCEMENT LETTER

EX-10.1

Filename: ea029662401ex10-1.htm · Sequence: 3

Exhibit 10.1

INMUE BIO INC.

225 NE Mizner Blvd., Suite 640

Boca Raton, Florida 33432

June 29, 2026

To the Holder of April 2024 Common Stock Purchase

Warrants

Re: Inducement Offer to Exercise Existing Common Stock Purchase

Warrants

Dear Holder:

INMUNE BIO INC. (the “Company”)

is pleased to offer (this “Inducement Offer”) to you (“Holder”, “you” or similar

terminology) the opportunity to exercise 50% of the existing Warrant to Purchase Shares of Common Stock issued to you on April 24 and

April 29, 2024, as amended on December 22, 2025 (the “Warrants”), for a reduced exercise price equal to $1.40 (reduced from

$1.95), and to amend the Warrant such that the maturity date of the warrant, as it relates to the remaining 50% of the Warrant, shall

be extended from June 30, 2026 to December 31, 2027. The issuance, or resale, of shares of Common Stock underlying the Warrant have been

registered pursuant to an effective registration statement (File No. 333-254221). The shares of Common Stock underlying the Warrant are

referred to herein as the “Warrant Shares” and the registration statement referenced in the foregoing sentence is referred

to herein as the “Registration Statement.” The Registration Statement is currently effective and, upon exercise of

50% the Warrant pursuant to this letter agreement (the “Inducement Agreement,” and together with the Second Amendment

to Warrant to Purchase Shares of Common Stock (as defined below), the “Transaction Documents”), will be effective for

the issuance or resale of the Warrant Shares, as applicable. Capitalized terms not otherwise defined herein shall have the meanings set

forth in the Second Amendment to Warrant to Purchase Shares of Common Stock (as defined hereinafter).

The Company is making you

this offer during the period from the date of this Inducement Offer set forth above and until 5:00 pm, Eastern Time, on June 30, 2026

(the “Exercise Period”). Exercise of 50% of the Warrant may be made during the Exercise Period by delivery to the Company

of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise attached to the Warrants,

as applicable; provided, that the exercise of 50% the Warrant will be accompanied by payment in full of the Reduced Exercise

Price (as defined below) to the Company and that The Holder will execute and return the Form of the Second Amendment to Warrant to Purchase

Shares of Common Stock to the Company, together with the Amendment Consideration, no later than June 30, 2026, by 5:00pm, Eastern

Time.

The Company desires to reduce

the Exercise Price (as defined in the Warrants) of the 50% of the Warrant held by each Holder (the “Reduced Warrants”) to

$1.40 per share of Common Stock (the “Reduced Exercise Price”). In consideration for the Reduced Exercise Price and

exercising the Reduced Warrants held by Holder pursuant to the terms of this Inducement Offer (the “Warrant Exercise”),

the Company hereby offers to amend the Warrant to extend the maturity date of the remaining Warrants (other than the Reduced Warrants)

from June 30, 2026 to December 31, 2027, which such amendment shall be substantially in the form as set forth in Exhibit A

hereto (the “Second Amendment to Warrant to Purchase Shares of Common Stock”).

Notwithstanding anything herein

to the contrary, in the event that any Warrant Exercise would otherwise cause the Holder to exceed the beneficial ownership limitations

(“Beneficial Ownership Limitation”) set forth in Section 2(d)(viii) of Warrant (or, if applicable and at the Holder’s

election, 9.99%), the Company shall only issue such number of Warrant Shares to the Holder that would not cause the Holder to exceed the

maximum number of Warrant Shares permitted thereunder, as directed by the Holder, with the balance to be held in abeyance until notice

from the Holder that the balance (or portion thereof) may be issued in compliance with such limitations, which abeyance shall be evidenced

through the Warrants which shall be deemed prepaid thereafter (including the payment in full of the exercise price), and exercised pursuant

to a Notice of Exercise in the Warrant (provided no additional exercise price shall be due and payable). The parties hereby agree that

the Beneficial Ownership Limitation for purposes of the Warrant is as set forth on the Holder’s signature page hereto.

Expressly subject to the

paragraph immediately following this paragraph below, Holder may accept this offer by signing this letter below and the Form of the Second

Amendment to Warrant to Purchase Shares of Common Stock, which constitutes the Holder’s acceptance to exercise 50% of the Warrant

at the Holder’s own discretion subject to the Beneficial Ownership Limitation set forth in Section 2(d)(viii) of the Warrant.

The Company agrees to the

representations, warranties and covenants set forth on Annex A attached hereto as of the date hereof and as of the Closing

Date.

The Holder represents

and warrants that, as of the date hereof, the Holder is fully aware of, and has reviewed all of the Company’s public filings.

Holder represents and warrants

that, as of the date hereof it is, and on each date on which it exercises any New Warrants it will be, an “accredited investor”

as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”).

If this offer is accepted

and the transaction documents are executed, the Company shall issue a press release and/or file a Current Report on Form 8-K with the

Commission disclosing all material terms of the transactions contemplated hereunder, including this letter agreement as an exhibit thereto

with the Commission. From and after the issuance of such press release or filing of such Current Report on Form 8-K, as applicable, the

Company represents to you that it shall have publicly disclosed all material, non-public information delivered to you by the Company,

or any of its respective officers, directors, employees or agents in connection with the transactions contemplated hereunder. Notwithstanding

the foregoing, the Company shall not publicly disclose the name of any Holder, or include the name of any Holder in such press release

or Current Report on Form 8-K, without the prior written consent of such Holder. In addition, effective upon the issuance of such press

release and/or filing of such Current Report on Form 8-K, the Company acknowledges and agrees that any and all confidentiality or similar

obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers,

directors, agents, employees or Affiliates on the one hand, and you and your Affiliates on the other hand, shall terminate.

No later than the third (3rd)

Trading Day following the date hereof, the closing (“Closing”) shall occur at such location as the parties shall mutually

agree. The date of the Closing of the exercise of the Existing Common Warrants shall be referred to as the “Closing Date”.

Sincerely yours,

INMUNE BIO INC.

By:

Name:

Cory Ellspermann

Title:

Chief Financial Officer

[Holder Signature Page Follows]

Accepted and Agreed to:

Name of Holder: _________________________________________________________

Signature of Authorized Signatory of Holder:

______________________________________________________

Name of Authorized Signatory: ______________________________________________________

Title of Authorized Signatory: _____________________________________________________

Number of Warrants: _____________________________

Aggregate Warrant Exercise Price at the Reduced

Exercise Price being exercised contemporaneously with signing this letter agreement: ________________________________________________________________________

Existing Common Warrants Beneficial Ownership

Blocker: 4.99% or 9.99%

DTC Instructions: _________________________________________________

[Holder Signature Page]

FORM OF AMENDMENT TO WARRANT

This Second Amendment to Common Stock Purchase

Warrant (this “Amendment”) is entered into and shall become effective as of the date on which INmune Bio Inc. a Nevada corporation

(the “Company”) receives both (i) payment of the Amendment Consideration (as defined below) and (ii) a duly executed copy

of this Amendment from the undersigned holder (“Holder”) (such date, the “Effective Date”).

WHEREAS, the Holder is the holder of that certain

warrant issued by the Company to the Holder on April 24 or April 29, 2024 (the “Warrant”);

WHEREAS, the Company and the Holder desire to

amend the Warrant as more particularly set forth below in exchange for the Amendment Consideration; WHEREFORE, the parties do hereby agree

as follows:

1. The

portion of the Warrant’s first paragraph:

“and on or prior to 5:00pm (New York City

time) on June 30, 2026,”

is hereby amended and replaced with the following:

“and on or prior to 5:00pm (New York City

time) on December 31, 2027”

2. As

consideration for this Amendment, the Company has granted the Holder the option to exercise 50% of the warrant for a reduced exercise

price of $1.40 per share of Common Stock and the Holder elected to exercise 50% of the warrant for such reduced price and has paid the

Company such reduced exercised price (the “Amendment Consideration”). The effectiveness of this Amendment is expressly conditioned

upon the Company’s receipt of the full Amendment Consideration.

3. The

Holder must execute and return this Amendment to the Company, together with the Amendment Consideration, no later than June 30, 2026 (the

“Execution Deadline”). If the Holder does not execute and return this Amendment, together with the Amendment Consideration,

to the Company by the Execution Deadline, this Amendment shall be null and void and of no force or effect.

4. Except

as expressly amended herein, all terms and conditions of the Warrant shall remain in full force and effect.

5. This

Amendment shall be governed by and construed in accordance with the laws governing the Warrant.

6. This

Amendment may be executed in counterparts, each of which shall be deemed an original, and shall be binding upon all parties, their successors

and assigns, and all of which taken together shall constitute one and the same Amendment. A signature delivered by facsimile or email

shall constitute an original.

[Signature Page Follows]

INmune Bio Inc.

By:

Name:

Title:

Holder:

By:

Name:

Title:

Annex A

Representations, Warranties

and Covenants of the Company. The Company hereby makes the following representations and warranties to the Holder:

a) Subsidiaries.

All of the direct and indirect subsidiaries of the Company are set forth on the SEC Reports (as hereinafter defined). The Company owns,

directly or indirectly, all of the capital stock or other equity interests of each subsidiary free and clear of any liens, and all of

the issued and outstanding shares of capital stock of each subsidiary are validly issued and are fully paid, non-assessable and free of

preemptive and similar rights to subscribe for or purchase securities.

b) SEC Reports. The

Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities

Exchange Act of 1934, as amended (the “Exchange Act”), including pursuant to Section 13(a) or 15(d) thereof, for the

two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the

foregoing materials, including the exhibits thereto and documents incorporated by reference therein “SEC Reports”).

As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Exchange Act and none of

the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated

therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading

except as otherwise noted in a subsequent SEC Report. The Company has never been an issuer subject to Rule 144(i) under the Securities

Act.

c) Organization and Qualification.

The Company is an entity duly incorporated or otherwise organized, validly existing, under the laws of Nevada, in good standing under

the laws of the Nevada, with the requisite power and authority to own and use its properties and assets and to carry on its business as

currently conducted. The Company is not in violation nor default of any of the provisions of its certificate or articles of incorporation,

bylaws or other organizational or charter documents. The Company is duly qualified to conduct business and is in good standing as a foreign

corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification

necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected

to result in Material Adverse Effect (as defined below).

d) Authorization; Enforcement.

The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this letter

agreement and otherwise to carry out its obligations hereunder. The execution and delivery of this letter agreement by the Company and

the consummation by the Company of the transactions contemplated hereby have been duly authorized by all necessary action on the part

of the Company and no further action is required by the Company, its board of directors or its stockholders in connection herewith. This

letter agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid

and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable

principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement

of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief

or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

d) No Conflicts.

The execution, delivery and performance of this letter agreement by the Company and the consummation by the Company of the transactions

contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company’s certificate or articles of

incorporation, bylaws or other organizational or charter documents; or (ii) conflict with, or constitute a default (or an event that with

notice or lapse of time or both would become a default) under, result in the creation of any liens, claims, security interests, other

encumbrances or defects upon any of the properties or assets of the Company in connection with, or give to others any rights of termination,

amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement, credit facility, debt

or other material instrument (evidencing Company debt or otherwise) or other material understanding to which such Company is a party or

by which any property or asset of the Company is bound or affected; or (iii) conflict with or result in a violation of any law, rule,

regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject

(including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected,

except, in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a material adverse

effect upon the business, prospects, properties, operations, condition (financial or otherwise) or results of operations of the Company,

taken as a whole, or in its ability to perform its obligations under this letter agreement.

e) Trading Market.

The transactions contemplated under this letter agreement comply with all the rules and regulations of Nasdaq.

f) Filings, Consents

and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any

filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with

the execution, delivery and performance by the Company of this letter agreement, other than: (i) the filings required pursuant to this

letter agreement.

g) Material Changes;

Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included within the SEC

Reports, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material

Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued

expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in

the Company’s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not

altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to

its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company

has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock incentive plans.

The Company does not have pending before the Commission any request for confidential treatment of information. Except for the issuance

of the Securities contemplated by this Agreement or as set forth on the SEC Reports, no event, liability, fact, circumstance, occurrence

or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their

respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the

Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at

least 1 Trading Day prior to the date that this representation is made. For purposes hereof, “Material Adverse Effect”

means (i) a material adverse effect on the legality, validity or enforceability of the Transaction Documents, (ii) a material adverse

effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the subsidiaries,

taken as a whole, or (iii) a material adverse effect on the Company’s ability to perform in any material respect on a timely basis

its obligations under any Transaction Document.

h) Listing and Maintenance

Requirements. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no

action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under

the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. Except

as set forth on the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market

on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance

requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue

to be, in material compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic

transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the

fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Jun. 30, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 30, 2026

Entity File Number

001-38793

Entity Registrant Name

INMUNE BIO INC.

Entity Central Index Key

0001711754

Entity Tax Identification Number

47-5205835

Entity Incorporation, State or Country Code

Entity Address, Address Line One

225 NE Mizner Blvd.

Entity Address, Address Line Two

Suite 640

Entity Address, City or Town

Boca Raton

Entity Address, State or Province

Entity Address, Postal Zip Code

33432

City Area Code

561

Local Phone Number

710-0512

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.001 per shares

Trading Symbol

INMB

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration